242 related articles for article (PubMed ID: 15593198)
1. Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide.
Crans GG; Silverman SL; Genant HK; Glass EV; Krege JH
Arthritis Rheum; 2004 Dec; 50(12):4028-34. PubMed ID: 15593198
[TBL] [Abstract][Full Text] [Related]
2. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women.
Oglesby AK; Minshall ME; Shen W; Xie S; Silverman SL
J Rheumatol; 2003 Jul; 30(7):1579-83. PubMed ID: 12858462
[TBL] [Abstract][Full Text] [Related]
3. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study.
Salaffi F; Cimmino MA; Malavolta N; Carotti M; Di Matteo L; Scendoni P; Grassi W;
J Rheumatol; 2007 Jul; 34(7):1551-60. PubMed ID: 17516618
[TBL] [Abstract][Full Text] [Related]
4. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
Marcus R; Wang O; Satterwhite J; Mitlak B
J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
[TBL] [Abstract][Full Text] [Related]
5. Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis.
Silverman SL; Piziak VK; Chen P; Misurski DA; Wagman RB
J Rheumatol; 2005 Dec; 32(12):2405-9. PubMed ID: 16331772
[TBL] [Abstract][Full Text] [Related]
6. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
[TBL] [Abstract][Full Text] [Related]
7. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
[TBL] [Abstract][Full Text] [Related]
8. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
[TBL] [Abstract][Full Text] [Related]
9. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
10. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
[TBL] [Abstract][Full Text] [Related]
11. Impact of recent fracture on health-related quality of life in postmenopausal women.
Brenneman SK; Barrett-Connor E; Sajjan S; Markson LE; Siris ES
J Bone Miner Res; 2006 Jun; 21(6):809-16. PubMed ID: 16753011
[TBL] [Abstract][Full Text] [Related]
12. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures.
Oleksik A; Lips P; Dawson A; Minshall ME; Shen W; Cooper C; Kanis J
J Bone Miner Res; 2000 Jul; 15(7):1384-92. PubMed ID: 10893688
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
Silverman SL; Shen W; Minshall ME; Xie S; Moses KH
J Rheumatol; 2007 Jan; 34(1):140-4. PubMed ID: 17216681
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
[TBL] [Abstract][Full Text] [Related]
17. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
18. Back pain treatment in post-menopausal osteoporosis with vertebral fractures.
Ulivieri FM
Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):21-3. PubMed ID: 18180603
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
[TBL] [Abstract][Full Text] [Related]
20. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
Maugeri D; Russo E; Luca S; Leotta C; Mamazza G; Sorace R; Rizzotto M; Manuele S; Fiore V; Taverna G; Castiglia B; Calitro M
Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
